Get the Stockscreener App
8.55
0.59%
0.05
Kura Oncology Inc stock is traded at $8.55, with a volume of 2.25M.
It is up +0.59% in the last 24 hours and up +5.95% over the past month.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
See More
Previous Close:
$8.50
Open:
$8.56
24h Volume:
2.25M
Relative Volume:
1.51
Market Cap:
$744.00M
Revenue:
-
Net Income/Loss:
$-168.09M
P/E Ratio:
-3.9401
EPS:
-2.17
Net Cash Flow:
$-138.01M
1W Performance:
-0.12%
1M Performance:
+5.95%
6M Performance:
+5.17%
1Y Performance:
+16.64%
1-Day Range:
$8.16
$8.62
1-Week Range:
$8.16
$8.76
52-Week Range:
$5.41
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
Name
Kura Oncology Inc
Sector
Industry
Phone
(858) 500-8800
Address
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
8.55 | 739.65M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Initiated | Guggenheim | Neutral |
| Feb-06-25 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-14-24 | Downgrade | Stifel | Buy → Hold |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Aug-11-23 | Initiated | BofA Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| May-17-23 | Initiated | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jul-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-15-22 | Initiated | Jefferies | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-07-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Nov-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| May-05-20 | Initiated | Barclays | Overweight |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Nov-09-18 | Initiated | Piper Jaffray | Overweight |
| Aug-01-18 | Initiated | H.C. Wainwright | Buy |
| Oct-13-16 | Resumed | Leerink Partners | Outperform |
| Jan-22-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-30-15 | Initiated | Oppenheimer | Outperform |
| Dec-16-15 | Initiated | Citigroup | Buy |
View All
Kura Oncology Inc Stock (KURA) Latest News
Kura Oncology at TD Cowen Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada
Kura Oncology (KURA) Set to Release Q4 Earnings - GuruFocus
A Glimpse of Kura Oncology's Earnings Potential - Benzinga
Kura Oncology Inc expected to post a loss of 61 cents a shareEarnings Preview - TradingView
Kura Oncology (KURA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Wall Street Zen Downgrades Kura Oncology (NASDAQ:KURA) to Sell - MarketBeat
(KURA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Kura Oncology (NASDAQ:KURA) Upgraded at Zacks Research - MarketBeat
Kura Oncology, Inc. (NASDAQ:KURA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
KURA Should I Buy - Intellectia AI
Kura Oncology, Inc. (KURA): Investor Outlook Reveals 275% Upside Potential - DirectorsTalk Interviews
KURA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Kura Oncology to Participate in Three Upcoming Investor Conferences - marketscreener.com
Biotech firm Kura Oncology maps three March investor talks - Stock Titan
Kura Oncology (NASDAQ:KURA) Rating Increased to Hold at Wall Street Zen - MarketBeat
Will Kura Oncology Inc. stock benefit from upcoming earnings reportsPrice Action & Consistent Profit Focused Trading Strategies - mfd.ru
Kura Oncology, Inc. (KURA): Investor Outlook With A Promising 278% Potential Upside - DirectorsTalk Interviews
Earnings Preview: Kura Oncology (KURA) Q4 Earnings Expected to Decline - Finviz
Kura Oncology (KURA) to Release Quarterly Earnings on Wednesday - MarketBeat
Liquidity Mapping Around (KURA) Price Events - Stock Traders Daily
Kura Oncology (NASDAQ:KURA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
What is Kura Oncology Inc. s P E ratio telling us2025 Price Targets & Accurate Entry and Exit Point Alerts - mfd.ru
Kura Oncology (NASDAQ:KURA) Share Price Crosses Below 50-Day Moving AverageHere's Why - MarketBeat
IPO Launch: Is Kura Oncology Inc a strong candidate for buy and holdJuly 2025 Retail & Free Verified High Yield Trade Plans - baoquankhu1.vn
Is Kura Oncology Inc. vulnerable to short sellersPortfolio Return Report & Daily Price Action Insights - mfd.ru
The Truth About Kura Oncology Inc: Is This Sleeper Cancer Stock About To Explode? - AD HOC NEWS
Kura Oncology (KURA) Issues Stock Options to New Employees - GuruFocus
Kura Oncology Grants Inducement Stock Options to New Employees as Part of 2023 Inducement Option Plan - Quiver Quantitative
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Need To Know: The Consensus Just Cut Its Kura Oncology, Inc. (NASDAQ:KURA) Estimates For 2026 - simplywall.st
Why (KURA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Barclays Remains a Buy on Kura Oncology (KURA) - The Globe and Mail
Analyst flags Kura Oncology, Inc. (KURA) for 2026 milestones and pipeline expansion - MSN
Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Analyst Flags Kura Oncology, Inc. (KURA) for 2026 Milestones and Pipeline Expansion - Finviz
Citizens reiterates Market Outperform rating on Kura Oncology stock By Investing.com - Investing.com Canada
ETF Watch: Is AVDL vulnerable to short sellers2025 Top Decliners & High Accuracy Investment Entry Signals - baoquankhu1.vn
Treasury Yields: Whats the profit margin of Kura Oncology IncWeekly Trend Report & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Nan Fung Trinity HK Ltd. Invests $2.04 Million in Kura Oncology, Inc. $KURA - MarketBeat
Kura Oncology, Inc. (KURA) Growth Potential: Analyst Ratings Suggest A 295.93% Upside - DirectorsTalk Interviews
Kura Oncology Tightens Governance with Amended Bylaws - TipRanks
Don't Ignore The Insider Selling In Kura Oncology - simplywall.st
Insider Selling: Kura Oncology (NASDAQ:KURA) Insider Sells 6,414 Shares of Stock - MarketBeat
Why is Kura Oncology Inc. stock going upWeekly Risk Report & Low Drawdown Trading Techniques - mfd.ru
Kura Oncology’s chief legal officer sells $94,827 in stock - Investing.com India
Kura oncology CSO Burrows sells $11k in shares By Investing.com - Investing.com Australia
Kura Oncology COO Ford sells $15,339 in stock By Investing.com - Investing.com UK
Kura Oncology’s chief legal officer sells $94,827 in stock By Investing.com - Investing.com UK
Kura Oncology (NASDAQ:KURA) Insider Mollie Leoni Sells 8,180 Shares - MarketBeat
Kathleen Ford Sells 1,813 Shares of Kura Oncology (NASDAQ:KURA) Stock - MarketBeat
Kura Oncology Inc Stock (KURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):